US 12,083,190 B2
Rabies vaccine
Margit Schnee, Constance (DE); Thomas Kramps, Tübingen (DE); Lothar Stitz, Rottenburg (DE); and Benjamin Petsch, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on May 17, 2022, as Appl. No. 17/746,844.
Application 17/746,844 is a division of application No. 16/865,107, filed on May 1, 2020, granted, now 11,369,694.
Application 16/865,107 is a division of application No. 15/048,356, filed on Feb. 19, 2016, granted, now 10,682,426, issued on Jun. 16, 2020.
Application 15/048,356 is a continuation of application No. PCT/EP2014/002298, filed on Aug. 21, 2014.
Claims priority of application No. PCT/EP2013/002517 (WO), filed on Aug. 21, 2013.
Prior Publication US 2022/0288239 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 39/205 (2006.01); A61K 39/42 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 16/10 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 48/0075 (2013.01) [A61K 9/0021 (2013.01); A61K 39/12 (2013.01); A61K 39/205 (2013.01); A61K 39/42 (2013.01); C07K 14/005 (2013.01); C07K 16/10 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/552 (2013.01); C12N 2760/20134 (2013.01)] 18 Claims
 
1. A method of stimulating a protective immune response to rabies virus in a subject comprising administering to the subject a pharmaceutical composition comprising a purified mRNA molecule, said mRNA comprising:
(a) a 5′ Cap;
(b) an open reading frame (ORF) encoding a Rabies virus glycoprotein (RAV-G), wherein the ORF comprises a sequence having at least about 95% identity to the protein coding region of SEQ ID NO: 24; and
(c) a Poly(A) sequence,
wherein the composition is administered by injection.